



Kiniksa to Present Late-Breaking KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology

August 29, 2018

HAMILTON, Bermuda, Aug. 29, 2018 (GLOBE NEWSWIRE) -- [Kiniksa Pharmaceuticals, Ltd.](#) (Nasdaq: KNSA) ("Kiniksa"), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it will present clinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta (OSMR β), at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris.

During the Late-Breaking News Session on Saturday, September 15th, 2018, Dr. Zamaneh Mikhak of Kiniksa will deliver an oral presentation of the company's placebo-controlled, double-blind, single-ascending-dose, Phase 1a/1b clinical trial of KPL-716.

This clinical trial evaluated the safety, tolerability, pharmacokinetics and immunogenicity of intravenous or subcutaneous KPL-716 in healthy volunteers and subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus. Atopic dermatitis served as a proxy for IL-31-driven pruritic diseases as a means to assess target engagement and a potential early signal of efficacy in reducing pruritus.

About KPL-716

KPL-716 is an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta (OSMR β), which mediates signaling of IL-31 and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation and fibrosis. Kiniksa believes KPL-716 to be the only monoclonal antibody in development that targets both pathways simultaneously.

About Kiniksa

Kiniksa is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. For more information, please visit www.kiniksa.com.

Every Second Counts!TM

Kiniksa Investor and Media Contact

Mark Ragosa
(781) 430-8289
mragosa@kiniksa.com



Source: Kiniksa Pharmaceuticals, Ltd.